GSC
LXEO icon

Ground Swell Capital’s Lexeo Therapeutics LXEO Stock Holding History

Ground Swell Capital’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,123
Closed -$80.2K – 209
2025
Q1 		$80.2K Buy
+23,123
New +$102K 0.17% 117

Other funds holding LXEO

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Ground Swell Capital's LXEO Position: Q2 2025 in Review

Ground Swell Capital sold out of Lexeo Therapeutics (LXEO) in Q2 2025, closing a stake of 23,123 shares — an estimated $80.2K sold.

Ground Swell Capital first reported a position in LXEO in Q1 2025 and held it in 1 quarter. The position peaked at $80.2K in Q1 2025. 90 funds tracked by Wall St. Rank hold LXEO as of Q2 2025.

  • Ground Swell Capital reported no remaining Lexeo Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ground Swell Capital sold 23,123 Lexeo Therapeutics shares in Q2 2025, an estimated $80.2K.
  • Ground Swell Capital first reported a position in Lexeo Therapeutics in Q1 2025 and held it in 1 quarter.
  • Ground Swell Capital's Lexeo Therapeutics position peaked at $80.2K in Q1 2025.
  • 90 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q2 2025.

Based on Ground Swell Capital's 13F filing for Q2 2025, filed 31 Jul 2025.